A recent study of a selected cohort of 212 IDH-wildtype GBM patients performed a more comprehensive molecular characterization of elderly GBM patients under WHO CNS5 classification and found that MGMT promoter methylation status and TERT promoter mutation status could not significantly distinguish the prognosis of elderly patients when these group of patients were analyzed alone (Fukai et al., 2020). This evidence concerns the gene MGMT and glioblastoma.